



UAMS IRB INFORMATION

IRB FEES TO INCREASE JULY 1ST

Effective July 1st, 2009, the UAMS IRB is increasing its IRB Fees, announced Mo Valentine, IRB Director. The following rate structure will be used for all protocols submitted after June 30th, 2009. The rates for funded projects submitted prior to July 1st, 2009 will be honored for the life of the project.

The PI must provide an account number for the IRB billing at the time of protocol submission. If the protocol is to be funded, Grants Accounting will allow an advance account to be set up to charge the fee. Otherwise, a department account must be provided and the fee transferred to the grant or clinical trial once it is set up. It is the goal of the IRB office to bill for the IRB fee within one week following the protocol review by the IRB.



Mo Valentine
UAMS IRB Director

Recharge Structure

Category	New Submission	Continuing Review	Payment Source
I Industry Funded			
a Industry-Sponsored (FDA/ICH regulated)	\$2,500	\$1,000	Contract/Study Acct
b Industry-Supported	\$750	\$400	Contract/Study Acct
c Drug/Device Provided without funding support	\$250	\$150	Investigator
II Non-federal grants, awards, gifts with no indirect (e.g. foundations, tobacco settlement)	\$300	\$150	Grant
III No funding or departmental funds (includes CUMG)	\$75	\$50	Investigator
IV Other (Specify) (e.g. multiple funding sources)	Negotiable	Negotiable	Negotiable

Special Cases:

Graduate Students, Fellows and Residents engaged in independent projects are exempt from this requirement (except for Industry Sponsored Clinical Trials).
All other requests for exemption will be reviewed on a case by case basis with ORSP and the Clinical Trials Office (Not for Industry Sponsored Clinical Trials).
Federal Projects are not charged.

SPOTLIGHT ON...

This month's SPOTLIGHT article is on Misty Ward Stevens, a native of Emerson, Arkansas who is the Operations Director for InterveXion Therapeutics, a company founded by UAMS employees Dr. Brooks Gentry and Dr. Michael Owens. The company is focused on the development of protective therapies using monoclonal antibodies. Misty has worked at InterveXion Therapeutics since June 2005 and is currently involved in addiction research, including developing therapies to treat methamphetamine abuse.

Misty holds an undergraduate degree in Horticulture and a Ph.D. in Biological Sciences from the University of Arkansas at Fayetteville. She also completed a Post Doctoral Fellowship at Harvard Medical School. She is currently pursuing a MBA in Management from the University of Arkansas. Misty is married to Dallas Stevens, a native of Jonesboro, Arkansas and they enjoy hiking in national parks in their spare time.



*Misty Ward Stevens, Ph.D.
Operations Director
InterveXion Therapeutics*

UPCOMING CLASSES AT ACHRI

RESEARCH COORDINATOR MEETING

Where: S-120 Sturgis Building Lunch will be served to the first 30 attendees

When: July 9, 2009 from 12:00 pm to 1:00 pm

This quarterly meeting gives research coordinators across campus a chance to assemble, network, and ask questions of ACHRI related to their projects and issues within the ACH/ACHRI research community.

For more information see the [Research Coordinator Network Homepage](#) or call Margie Brackeen at ACHRI at 501-364-3586.

DOT - IATA TRANSPORTING INFECTIOUS SUBSTANCES SAFELY

Where: Brandon Auditorium (South Campus)

When: July 21, 2009 from 9:00 am to 3:00 pm

This course is designed to satisfy the DOT and IATA training requirements for the shipment of hazardous materials or dangerous goods, focusing on 6.2 infectious substances. This course is required every 2 years.

To register:

ACH, ACNC, and ACHRI Employees register through the **ACH Training Site**

Go to: <https://secure.archchildrens.org/achtraining/myprofile/>

Department name: ACH Safety

Please contact Joe Knight at 501-680-1088 or by email at knightjl@archchildrens.org for more information.

COMPLIANCE INFORMATION

The UAMS Office of Research Compliance (ORC) is updating the ORC website. The goal of the new website is to make more information available to the UAMS research community.

The ORC home page (www.uams.edu/orc) contains quick links to the most commonly requested items. If you need to renew your human subject protection (remember, it expires after two years), click on the link for CITI training. The ORC home page also has links to request ARIA access and to see current research education offerings. Information about the Certified Research Specialist (CRS) program and the CRS exam is also accessible through home page links.

The “Tools for Best Practices” link directs viewers to helpful research related resources. Click around to learn about good clinical practices, UAMS offices that are available to help researchers, study regulatory binder requirements, and other helpful information. The policies and regulations that guide human subject research can be accessed through the “Reports and Regulations” link. Clicking on “Helpful Links” will take viewers to a list of institutional and national offices involved in research. There’s also a link that provides information about the research compliance hotline.

Planned Improvements

ORC staffers are also creating tools that researchers can use to do their own research process assessments. Researchers and their staffs will be able to use these tools to review their informed consent processes and documentation, subject records, and regulatory binders to help make sure they are meeting regulatory and institutional requirements. These self-assessments tools will be based upon the methods ORC uses when it does compliance reviews. These items are expected to be posted on the web site by the end of July.

IRB DOCUMENT TIP

When uploading a document in ARIA, ARIA will ask you for a document date. Make sure the date you enter is the date that is PRINTED ON the document, NOT the date you upload the document.

RESEARCH NEWSLETTER

Office of Research and
Sponsored Programs
4301 W. Markham, #812
Little Rock, AR 72205

Phone: 501-526-4862
Fax: 501-686-8359
E-mail:
doanleslie@uams.edu

HAPPY 4TH OF JULY!

